Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 09:30 ET | Source: Medigene AG

New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)

Martinsried/Munich, April 18, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
April 11, 2023 10:45 ET | Source: Medigene AG

Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting

Martinsried/Munich, April 11, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
April 04, 2023 10:00 ET | Source: Medigene AG

Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
April 03, 2023 12:45 ET | Source: Medigene AG

Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs

Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
March 29, 2023 01:30 ET | Source: Medigene AG

Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3...
March 28, 2023 11:00 ET | Source: Medigene AG

Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston

Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
March 20, 2023 06:00 ET | Source: Medigene AG

Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development

Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
March 16, 2023 05:00 ET | Source: Medigene AG

Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting

Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
March 15, 2023 11:47 ET | Source: Medigene AG

Medigene AG to report full year 2022 financial results on March 29, 2023

Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
March 10, 2023 12:00 ET | Source: Medigene AG

Medigene Amends 2022 Financial Guidance

MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right